Trazodone,
does it really help with Improved sleep onset, sleep maintenance, and sleep quality in chronic insomnia among adults without depression?
research showsTrazodone for chronic insomnia in adults without depression is rated D. In a large 14-day trial of 50 mg, subjective sleep latency improved by about 10 minutes, total sleep time by about 22 minutes, and wake after sleep onset by about 8 minutes, but none met AASM thresholds for clinical significance and sleep quality was not significantly better. A meta-analysis of seven randomized trials found small signals for perceived sleep quality and number of awakenings but no significant benefit for sleep efficiency, sleep latency, total sleep time, or wake after sleep onset. Some objective signals in a 2022 polysomnography meta-analysis came from small, short, heterogeneous populations including depression, substance dependence, and cerebrovascular disease, so they are not direct long-term evidence in nondepressed adults. AASM weakly recommends that clinicians not use trazodone for sleep-onset or sleep-maintenance insomnia in adults.
ads claimSedation at doses below antidepressant dosing is expanded into nondependence, long-term safety, preservation of natural sleep, and proven treatment of chronic insomnia. Feeling sleepy is not the same endpoint as restorative sleep or next-day function.
Useful facts when choosing a product
- Trazodone is a prescription antidepressant approved for depression; its use to treat insomnia is off label.
- Even low doses used for sleep can cause sedation, dizziness, orthostatic hypotension, and next-day cognitive or motor impairment.
- Rare but important risks include priapism, QT prolongation or arrhythmia, hyponatremia, and serotonin syndrome, requiring review of history and interacting medicines.
- Cognitive behavioral therapy for insomnia is first-line treatment for chronic insomnia, with evaluation for sleep apnea, restless legs, depression or anxiety, pain, medicines, and caffeine.
What the research actually shows
Walsh 1998 randomized 306 people to trazodone 50 mg, zolpidem 10 mg, or placebo for 14 days; trazodone effects were concentrated in the first week and fell below AASM clinical thresholds. Roth 2011 used a seven-day polysomnography crossover in 16 people with primary insomnia and found fewer awakenings and less stage-1 sleep, along with impaired memory, balance, and motor performance. Yi 2018 synthesized seven trials with 429 participants and found improvement only in perceived sleep quality and awakenings, not the other key measures. Zheng 2022 pooled polysomnography from 11 trials and 466 participants but included heterogeneous disorders, doses, and co-interventions and found no high-quality outcome evidence.
Why this is classified as D (32)
The largest short trial in nondepressed primary insomnia failed to cross clinical thresholds for every key measure, while meta-analyses show only small subjective and heterogeneous short-term polysomnographic signals. The absence of a large direct long-term trial and AASM opposition yield D with 32 points; sedation and orthostatic hypotension remain separate safety issues.
Counterpoint. A clinician may select a short off-label course for an individual after CBT-I is inadequate and alternatives are unsuitable. That does not raise population-level evidence or justify unsupervised long-term use.
Rejudgment record. New verdict — Integrated failure to meet clinical-significance thresholds in the short primary-insomnia trial, limited subjective and heterogeneous polysomnographic signals in meta-analyses, absence of a large direct long-term trial, and AASM opposition, while separating insomnia with depression
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Improved sleep onset, maintenance, and quality in chronic insomnia among adults without depression | D | The largest direct trial missed clinical thresholds, no large long-term trial exists, and AASM recommends against use. |
| Short-term improvement in perceived sleep quality and number of awakenings | C | A small positive meta-analytic signal exists, but subjective, small, short-term evidence imposes a C ceiling. |
| Improved insomnia comorbid with depression | ? | This is a separate clinical context confounded by antidepressant effects and was not evaluated in this verdict. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Walsh JK et al. 1998 | Multicenter randomized double-blind placebo- and active-controlled 14-day trial | 100 | Pharmaceutical product-trial context; detailed reporting limited | Subjective sleep latency, total sleep time, wake after sleep onset, and sleep quality | Small short-term improvements occurred, but none crossed AASM clinical-significance thresholds. | Largest direct short trial in nondepressed insomnia |
| Yi XY et al. 2018 | Meta-analysis of placebo-controlled randomized trials | 429 | Academic review; funding varied across included trials | Sleep efficiency, quality, latency, total sleep time, awakenings, and wake after sleep onset | Only perceived quality and number of awakenings were positive; sleep efficiency, latency, total sleep time, and wake after sleep onset were nonsignificant. | Key mixed synthesis |
| Sateia MJ et al. 2017 AASM | Evidence-based clinical practice guideline | 1 | American Academy of Sleep Medicine | Sleep onset, sleep maintenance, and harms in adult chronic insomnia | Weakly recommended that clinicians not use trazodone for sleep-onset or sleep-maintenance insomnia. | Guideline opposition |
Receipt — 4 References
All 4 cited sources were verified for existence at the original page (as of 2026-07-20).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-20 · Corrections: none
Cite this verdict
[Chamgap] Trazodone x improved sleep onset, maintenance, and quality in chronic insomnia among adults without depression — Evidence Grade D·32. 4 cited sources checked. Source: https://chamgap.com/en/verdicts/sleep/trazodone-chronic-insomnia-nondepressed-adults-sleep/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.